VN July 2021

Vetnuus | Julie 2021 12 The percentage of eosinophils (mean, 61% of the total nucleated cell population4) exceeds that of healthy dogs (5%-24%). 2,5,10 Samples can be obtained via tracheal wash or bronchoscopy. Bronchoscopy allows for visualisation of more characteristic airway associated changes (e.g., greenish-yellow secretions, irregular mucosa, hyperaemia). 2,5,11 Occasionally, intraluminal granulomas may be present, 4 allowing for mucosal brush samples or biopsies that can further support a diagnosis. Tracheal washes provide appropriate cytologic samples in most cases. Bronchoscopy is generally reserved for patients with more focal radiographic disease, concerns for neoplasia, or suspicion for concurrent structural disorders (e.g., bronchial collapse, tracheal collapse). Cytologic evaluation is critical to help rule out parasitic disease that can also result in eosinophilic inflammatory response. Faecal testing (i.e., Baermann test, faecal centrifugation) for parasitic disease is recommended; however, because negative results do not rule out parasitic disease, repeat testing and/or empirical therapy is advisable, particularly in at-risk patients. 12 Eosinophilic bronchitis (EB), eosinophilic granuloma (EG), and EBP have been retrospectively evaluated and may provide information regarding therapeutic response, indications for chronic therapy, and overall prognosis. 4 EB is associated with less severe airway remodelling, reduced eosinophilic inflammation (i.e., percent of nucleated cells in airway samples), reduced total inflammation (bronchoalveolar lavage total nucleated cell count/µL), and lower incidence of peripheral eosinophilia. Patients with EG demonstrate intraluminal granulomas/masses not present in EBP. Overlap still exists among these disorders, and the impact on therapeutic outcome is not yet known; however, EB may be more responsive and EG less responsive to therapy. 4 Eosinophilic pulmonarygranulomatosismayalsobeassociatedwitheosinophilic inflammation, but it is least common andmay represent a spectrum of disease characterised by masses that involve the pulmonary parenchyma (not exclusively luminal). EPG may also have systemic organ involvement and be the least responsive to therapy. 14,15 Corticosteroids are the mainstay of therapy. Prednisone is typically initiated at 1 to 2 mg/kg/day and gradually tapered to the lowest effective dose. 1,2,4 It is important to note that clinical relapse is common and can reach ≈30% after corticosteroids are tapered. 5 In some cases, medications can be discontinued after months with no evidence of relapse. Some clinicians may taper the drug faster, but the author believes that tapering faster than 1 to 2 weeks may increase the rate of relapse. Patients with severe signs (e.g., hypoxemia, oxygen dependency, alveolar disease) may also benefit from higher doses initially. Alternativeoptions formanagement include inhaledcorticosteroids or additional immunosuppressive medications. Fluticasone has been evaluated and may be successful in some cases but is not always adequate for maintaining clinical remission. 16 The author has successfully used cyclosporine in some cases inwhich corticosteroid adverse effects were intolerable. However, cyclosporine and other immunosuppressive drugs (e.g., azathioprine, mycophenolate) have not been evaluated in randomised, controlled studies despite sporadic clinical use. Cyclosporine has been used for the treatment of other eosinophilic disorders in dogs. 17,18 Content from Around the Globe, FREE. Subscribe to Global Brief , the weekly global Clinician’s Brief newsletter. It's FREE for all members of WSAVA associations. GLOBAL CONTENT DELIVERED DIRECTLY TO YOU SUBSCRIBE TODAY AT CLINICIANSBRIEF.COM/GLOBAL COMMON FINDINGS IN EOSINOPHILIC BRONCHOPNEUMOPATHY Clinical signs Coughing Acute respiratory distress Radiographic evaluation Bronchointerstitial pattern Peribronchial cuffing Alveolar disease Bronchiectasis Nodular pattern CBC Leukocytosis ± eosinophilia Airway cytology Eosinophilic ± neutrophilic airway cytology Airway culture Generally negative Bronchoscopy Greenish-yellow secretions Irregular, hyperemic mucosa ± nodular changes TAKE-HOME MESSAGES • EBP should be considered in patients with chronic cough and in patients with acute respiratory distress. • Radiographs may reveal nodules, mimicking neoplasia. • Absence of eosinophilia does not rule out the disease. • Diagnosis requires cytologic evaluation. • Parasitic disease can mimic EBP and cannot be defini­ tively ruled out with negative testing. • Corticosteroids (i.e., prednisone) are the hallmark of therapy. • Patient relapse is common and may necessitate long- term management. • Inhaled steroids may not always control the disease. v Article Chronic & Persistent Coughing in a Dog<<< 11

RkJQdWJsaXNoZXIy OTc5MDU=